What is Flamel Technologies?
Headquartered in Lyon, France, Flamel Technologies operates at the intersection of pharmaceutical innovation and advanced drug delivery systems. The company is recognized for its proprietary Micropump, LiquiTime, and Medusa platforms, which are engineered to enhance the safety and efficacy of both chemical and biological therapeutic agents. Beyond its R&D capabilities, Flamel maintains a robust commercial presence, notably through the marketing of Bloxiverz and the manufacturing of microparticles for high-profile partners like GlaxoSmithKline. Its business model effectively balances internal product development with strategic manufacturing partnerships, ensuring a diversified revenue stream across its French and American operations.
How much funding has Flamel Technologies raised?
Flamel Technologies has raised a total of $15M across 1 funding round:
Debt
$15M
Debt (2013): $15M, investors not publicly disclosed
Key Investors in Flamel Technologies
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Flamel Technologies?
With this major strategic investment, Flamel Technologies is well-positioned to accelerate the clinical development of its pipeline, particularly those assets utilizing the Medusa delivery platform. The company's focus remains on addressing unmet medical needs through abuse-deterrent formulations and optimized drug delivery, which are critical areas for long-term value creation. As the firm scales its operations, the integration of these capital resources will likely facilitate broader market penetration for its specialty products and strengthen its competitive moat in the highly regulated pharmaceutical landscape. Future growth will be driven by the successful transition of its clinical-stage candidates into commercialized assets, further cementing its reputation as a leader in pharmaceutical formulation technology.
See full Flamel Technologies company page
